Mroczek Magdalena, Maniscalco Ignazio, Sendel Manon, Baron Ralf, Seifritz Erich, Nowak Albina
Department of Neurology and Neurophysiology, Balgrist University Hospital, University of Zurich, Zurich, Switzerland.
Department of Geriatric Psychiatry, Psychiatric Hospital of University of Zurich, Zurich, Switzerland.
Front Psychiatry. 2022 Mar 16;13:829128. doi: 10.3389/fpsyt.2022.829128. eCollection 2022.
Patients suffering from Fabry disease (FD) have an increased risk of developing neuropsychiatric symptoms (NPS), mostly impairment in cognitive performance and depression. Single cases of psychosis have been reported, however, their association with FD can be coincidental. Furthermore, deficits in social functioning and adaptation as well as specific coping styles in FD patients were observed. Recent studies focused on a longitudinal course of the disease and identified risk factors associated with specific NPS. Since 2001, enzyme replacement therapy (ERT) has been available and in preliminary studies seems to improve cognitive impairment and adaptive skills. In this systematic review, we analyze the available literature on the NPS in FD and investigate if there are any differences in their distribution between males and females, children/adolescents and adults, and individuals treated with ERT and untreated. We discuss the role of the psychological, environmental, and molecular alterations and their correlation to psychiatric manifestations in FD. Finally, we would like to increase awareness of the spectrum of NPS in FD.
患有法布里病(FD)的患者出现神经精神症状(NPS)的风险增加,主要表现为认知功能受损和抑郁。虽然有单例精神病的报道,但其与FD的关联可能是偶然的。此外,还观察到FD患者存在社交功能和适应能力缺陷以及特定的应对方式。最近的研究聚焦于该疾病的纵向病程,并确定了与特定NPS相关的风险因素。自2001年以来,已有酶替代疗法(ERT),初步研究似乎显示其可改善认知障碍和适应技能。在本系统评价中,我们分析了关于FD中NPS的现有文献,并调查男性与女性、儿童/青少年与成年人以及接受ERT治疗和未接受治疗的个体之间NPS分布是否存在差异。我们讨论了心理、环境和分子改变的作用及其与FD精神症状表现的相关性。最后,我们希望提高对FD中NPS谱的认识。